Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.

Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T.

Ann Hematol. 2014 Jun;93(6):957-63. doi: 10.1007/s00277-014-2013-4. Epub 2014 Jan 19.

PMID:
24441947
2.

Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.

Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF.

Clin Cancer Res. 2005 Feb 15;11(4):1372-9.

3.

Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis.

Chen CY, Chou WC, Tsay W, Tang JL, Yao M, Huang SY, Tien HF.

BMC Cancer. 2013 Mar 8;13:107. doi: 10.1186/1471-2407-13-107.

4.

Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.

Fos J, Pabst T, Petkovic V, Ratschiller D, Mueller BU.

Blood. 2011 May 5;117(18):4881-4. doi: 10.1182/blood-2010-11-320747. Epub 2011 Mar 9.

5.

GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.

Hou HA, Lin YC, Kuo YY, Chou WC, Lin CC, Liu CY, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.

Ann Hematol. 2015 Feb;94(2):211-21. doi: 10.1007/s00277-014-2208-8. Epub 2014 Sep 21.

PMID:
25241285
6.

CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.

Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H.

Hum Pathol. 2013 Oct;44(10):2038-46. doi: 10.1016/j.humpath.2013.03.007. Epub 2013 May 21.

PMID:
23701943
7.

[The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].

Liu YR, Chang Y, Ruan GR, Qin YZ, Lai YY, Shi HX, Wang YZ, Li LD, Jiang B, Li JL.

Zhonghua Xue Ye Xue Za Zhi. 2013 Feb;34(2):98-103. Chinese.

PMID:
23611213
8.

Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.

Ferrari A, Bussaglia E, Úbeda J, Facchini L, Aventin A, Sierra J, Nomdedéu JF.

Hematol Oncol. 2012 Sep;30(3):109-14. doi: 10.1002/hon.1011. Epub 2011 Aug 3.

PMID:
21812014
9.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

10.

Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.

Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group.

Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24.

PMID:
22362118
11.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
12.

Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.

Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.

Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Erratum in: Ann Hematol. 2016 Jan;95(2):363.

PMID:
26537612
13.

[Immunologic characteristics and prognosis of acute myeloid leukemia M1].

Zhao F, Chen Y.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Aug;15(4):687-91. Chinese.

PMID:
17708783
14.

NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes.

Liu YR, Zhu HH, Ruan GR, Qin YZ, Shi HX, Lai YY, Chang Y, Wang YZ, Lu D, Hao L, Li JL, Li LD, Jiang B, Huang XJ.

Leuk Res. 2013 Jul;37(7):737-41. doi: 10.1016/j.leukres.2013.03.009. Epub 2013 Apr 16.

PMID:
23601747
15.

Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.

Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW.

Leuk Res. 2011 Feb;35(2):200-7. doi: 10.1016/j.leukres.2010.09.018. Epub 2010 Oct 20.

PMID:
20970189
16.

Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.

Casasnovas RO, Slimane FK, Garand R, Faure GC, Campos L, Deneys V, Bernier M, Falkenrodt A, Lecalvez G, Maynadié M, Béné MC.

Leukemia. 2003 Mar;17(3):515-27.

PMID:
12646939
17.

[Relationship between immunological characteristics and prognosis in children with acute myeloid leukemia].

Gu LJ, Tie LJ, Jiang LM, Chen J, Pan C, Dong L, Chen J, Xue HL, Tang JY, Wang YP, Ye H.

Zhongguo Dang Dai Er Ke Za Zhi. 2009 Apr;11(4):241-5. Chinese.

PMID:
19374802
18.

[Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].

Liu YR, Wang YZ, Chen SS, Chang Y, Fu JY, Li LD, Wang H, Yu H, Jiang B, Huang XJ.

Zhonghua Xue Ye Xue Za Zhi. 2007 Nov;28(11):731-6. Chinese.

PMID:
18457262
19.

Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size.

Nomdedeu J, Bussaglia E, Villamor N, Martinez C, Esteve J, Tormo M, Estivill C, Queipo MP, Guardia R, Carricondo M, Hoyos M, Llorente A, Juncà J, Gallart M, Domingo A, Bargay J, Mascaró M, Moraleda JM, Florensa L, Ribera JM, Gallardo D, Brunet S, Aventin A, Sierra J; Spanish CETLAM.

Leuk Res. 2011 Feb;35(2):163-8. doi: 10.1016/j.leukres.2010.05.015. Epub 2010 Jun 9.

PMID:
20542566
20.

Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.

Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X.

Cancer. 2008 Feb 1;112(3):572-80.

Supplemental Content

Support Center